{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:50:48Z","timestamp":1790272248409,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.yebeh.2024.109826","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:19:35Z","timestamp":1715948375000},"page":"109826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Use of perampanel oral suspension for the treatment of refractory and super-refractory status epilepticus"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-3255","authenticated-orcid":false,"given":"G.","family":"Bruschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kassabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Favaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dainese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.yebeh.2024.109826_b0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2024.109826_b0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archneurol.2010.169","article-title":"Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review","volume":"67","author":"Neligan","year":"2010","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2024.109826_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/epi.14515","article-title":"Long-term outcomes of status epilepticus: A critical assessment","volume":"59","author":"Sculier","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109826_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.2407","article-title":"Outcomes and treatment approaches for super-refractory status epilepticus: A systematic review and meta-analysis","author":"Cornwall","year":"2023","journal-title":"JAMA Neurol"},{"issue":"Suppl 11","key":"10.1016\/j.yebeh.2024.109826_b0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1528-1167.2005.00409.x","article-title":"Mortality after a first episode of status epilepticus in the United States and Europe","volume":"46","author":"Logroscino","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109826_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2024.109826_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106675","article-title":"Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy","volume":"102","author":"Minicucci","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109826_b0040","first-page":"559","article-title":"Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus","volume":"28","author":"Trinka","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.yebeh.2024.109826_b0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.seizure.2021.04.026","article-title":"Combining perampanel and ketamine in super refractory post-traumatic status epilepticus: A case report","volume":"89","author":"Manganotti","year":"2021","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109826_b0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13312-020-1759-0","article-title":"Refractory and super-refractory status epilepticus","volume":"57","author":"Samanta","year":"2020","journal-title":"Indian Pediatr"},{"issue":"Suppl 12","key":"10.1016\/j.yebeh.2024.109826_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2009.02357.x","article-title":"The proceedings of the innsbruck colloquium on status epilepticus","volume":"50","author":"Trinka","year":"2009","journal-title":"Epilepsia"},{"issue":"Pt 10","key":"10.1016\/j.yebeh.2024.109826_b0060","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2024.109826_b0065","doi-asserted-by":"crossref","unstructured":"Ochoa JG, Dougherty M, Papanastassiou A, Gidal B, Mohamed I, Vossler DG. Treatment of super-refractory status epilepticus: A review. Epilepsy Curr. Published online March 10, 2021. doi:10.1177\/1535759721999670.","DOI":"10.1177\/1535759721999670"},{"issue":"34","key":"10.1016\/j.yebeh.2024.109826_b0070","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1523\/JNEUROSCI.4944-04.2005","article-title":"Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J Neurosci"},{"issue":"23","key":"10.1016\/j.yebeh.2024.109826_b0075","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1523\/JNEUROSCI.0900-05.2005","article-title":"Status epilepticus increases the intracellular accumulation of GABAA receptors","volume":"25","author":"Goodkin","year":"2005","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.yebeh.2024.109826_b0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/jcm5050049","article-title":"Treatment of established status epilepticus","volume":"5","author":"Falco-Walter","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2024.109826_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109826_b0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","article-title":"Epilepsy: perampanel-new promise for refractory epilepsy?","volume":"8","author":"L\u00f6scher","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109826_b0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2024.109826_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.63","article-title":"Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model","volume":"2","author":"Hanada","year":"2014","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.yebeh.2024.109826_b0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","article-title":"Perampanel in the treatment of status epilepticus: A systematic review of the literature","volume":"86","author":"Brigo","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109826_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108583","article-title":"Perampanel in achieving status epilepticus cessation: A systematic review","volume":"128","author":"Perez","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2024.109826_b0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.14492","article-title":"Efficacy and safety of perampanel oral loading in postanoxic super-refractory status epilepticus: A pilot study","volume":"59","author":"Beretta","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109826_b0120","article-title":"Super-refractory status epilepticus treated with high dose perampanel: case series and review of the literature","volume":"2019","author":"Newey","year":"2019","journal-title":"Case Rep Crit Care"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109826_b0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13760-013-0225-3","article-title":"Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus","volume":"114","author":"R\u00f6sche","year":"2014","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2024.109826_b0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ebcr.2019.01.008","article-title":"Perampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome","volume":"11","author":"Santamarina","year":"2019","journal-title":"Epilepsy Behav Case Rep"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109826_b0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2024.109826_b0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/epi.14494","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: A single-center audit of 30 patients","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109826_b0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109826_b0150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5414\/CP203781","article-title":"Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects","volume":"58","author":"Shiba","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109826_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNP.0000000000000806","article-title":"American clinical neurophysiology society's standardized critical care EEG terminology: 2021 version","volume":"38","author":"Hirsch","year":"2021","journal-title":"J Clin Neurophysiol"},{"issue":"11","key":"10.1016\/j.yebeh.2024.109826_b0160","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.wnl.0000223352.71621.97","article-title":"A clinical score for prognosis of status epilepticus in adults","volume":"66","author":"Rossetti","year":"2006","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2024.109826_b0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/epi.14082","article-title":"The role of AMPA receptors and their antagonists in status epilepticus","volume":"59","author":"Leo","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109826_b0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ene.12531","article-title":"Early predictors of refractory status epilepticus: an international two-center study","volume":"22","author":"Sutter","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2024.109826_b0175","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.2147\/IJGM.S295855","article-title":"Epidemiology and outcomes of status epilepticus","volume":"14","author":"Ascoli","year":"2021","journal-title":"Int J Gen Med"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109826_b0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00415-012-6644-x","article-title":"Treatment deviating from guidelines does not influence status epilepticus prognosis","volume":"260","author":"Rossetti","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2024.109826_b0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2018.03.027","article-title":"Does semiology of status epilepticus have an impact on treatment response and outcome?","volume":"83","author":"Baysal-Kirac","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"13","key":"10.1016\/j.yebeh.2024.109826_b0190","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","article-title":"Pharmacotherapy for status epilepticus","volume":"75","author":"Trinka","year":"2015","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.yebeh.2024.109826_b0195","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","article-title":"Drug absorption, distribution, metabolism and excretion considerations in critically ill adults","volume":"9","author":"Roberts","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109826_b0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MCO.0b013e32835c1fa5","article-title":"Gastrointestinal dysmotility: evidence and clinical management","volume":"16","author":"Chapman","year":"2013","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"8","key":"10.1016\/j.yebeh.2024.109826_b0205","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109826_b0210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"67","key":"10.1016\/j.yebeh.2024.109826_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2019.02.022","article-title":"Plasma concentration and clinical effects of perampanel-The Kork experience [published correction appears in seizure","volume":"2019","author":"Steinhoff","year":"2019","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.yebeh.2024.109826_b0220","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1007\/s00415-021-10506-9","article-title":"Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review","volume":"268","author":"Lim","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2024.109826_b0225","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2015.04.005","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit","volume":"49","author":"Rohracher","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024002075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024002075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T01:23:23Z","timestamp":1738459403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024002075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":45,"alternative-id":["S1525505024002075"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109826","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of perampanel oral suspension for the treatment of refractory and super-refractory status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109826"}}